Arlette Scheifes1, Sanne Walraven2, Joost Jan Stolker3, Henk L I Nijman4, Toine C G Egberts5, Eibert R Heerdink6. 1. Department of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, PO Box 80082, 3508 TB Utrecht, The Netherlands; Altrecht Aventurijn, Vuurvlinder 4, 3734 AB, Den Dolder, The Netherlands. Electronic address: a.scheifes@uu.nl. 2. Department of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, PO Box 80082, 3508 TB Utrecht, The Netherlands. Electronic address: s.walraven@students.uu.nl. 3. Department of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, PO Box 80082, 3508 TB Utrecht, The Netherlands; Licht-Zorg, psychiatric care, De Hoopkade 22, 3604 DZ Maarssen, The Netherlands. Electronic address: joostjan.stolker@gmail.com. 4. Altrecht Aventurijn, Vuurvlinder 4, 3734 AB, Den Dolder, The Netherlands; Behavioural Science Institute (BSI), Faculty of Social Sciences, Radboud University Nijmegen, PO Box 9104, 6500 HE Nijmegen, The Netherlands. Electronic address: h.nijman@altrecht.nl. 5. Department of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, PO Box 80082, 3508 TB Utrecht, The Netherlands; Department of Clinical Pharmacy, University Medical Centre Utrecht, PO Box 85500, 3508 GA Utrecht, The Netherlands. Electronic address: a.c.g.egberts@uu.nl. 6. Department of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, PO Box 80082, 3508 TB Utrecht, The Netherlands; Altrecht Aventurijn, Vuurvlinder 4, 3734 AB, Den Dolder, The Netherlands; Department of Clinical Pharmacy, University Medical Centre Utrecht, PO Box 85500, 3508 GA Utrecht, The Netherlands. Electronic address: e.r.heerdink@uu.nl.
Abstract
BACKGROUND: Psychotropic drugs are prescribed to approximately 30-40% of adults with intellectual disability (ID) and challenging behaviour, despite the limited evidence of effectiveness and the potential of adverse events. AIMS: To assess the prevalence of adverse events in association with psychotropic drug use in adults with ID and challenging behaviour and to examine the relation of these adverse events with the person's quality of life. METHOD: The presence of adverse events was measured with a questionnaire that had to be filled in by the physicians of the participants. Movement disorders were measured separately with a standardised protocol. The strength of the association between adverse events and Intellectual Disability Quality of Life-16 (IDQOL-16), and daily functioning was investigated using linear regression analyses, taking into account the severity of disease (CGI-S) as potential confounder. RESULTS: Virtually all of 103 adults with ID and challenging behaviour had at least one adverse event (84.4%) and almost half had ≥3 adverse events (45.6%) across different subclasses. Using psychotropic drugs increased the prevalence of adverse events significantly. Respectively 13% of the patients without psychotropic drugs and 61% of the patients with ≥2 psychotropic drugs had ≥3 adverse events. Having adverse events had a significantly negative influence on the quality of life. CONCLUSIONS: A large majority of all patients had at least one adverse event associated with psychotropic drug use. More attention is needed for these adverse events and their negative influence on the quality of life of these patients, taking into account the lack of evidence of effectiveness of psychotropic drugs for challenging behaviour.
BACKGROUND: Psychotropic drugs are prescribed to approximately 30-40% of adults with intellectual disability (ID) and challenging behaviour, despite the limited evidence of effectiveness and the potential of adverse events. AIMS: To assess the prevalence of adverse events in association with psychotropic drug use in adults with ID and challenging behaviour and to examine the relation of these adverse events with the person's quality of life. METHOD: The presence of adverse events was measured with a questionnaire that had to be filled in by the physicians of the participants. Movement disorders were measured separately with a standardised protocol. The strength of the association between adverse events and Intellectual Disability Quality of Life-16 (IDQOL-16), and daily functioning was investigated using linear regression analyses, taking into account the severity of disease (CGI-S) as potential confounder. RESULTS: Virtually all of 103 adults with ID and challenging behaviour had at least one adverse event (84.4%) and almost half had ≥3 adverse events (45.6%) across different subclasses. Using psychotropic drugs increased the prevalence of adverse events significantly. Respectively 13% of the patients without psychotropic drugs and 61% of the patients with ≥2 psychotropic drugs had ≥3 adverse events. Having adverse events had a significantly negative influence on the quality of life. CONCLUSIONS: A large majority of all patients had at least one adverse event associated with psychotropic drug use. More attention is needed for these adverse events and their negative influence on the quality of life of these patients, taking into account the lack of evidence of effectiveness of psychotropic drugs for challenging behaviour.
Authors: Maria G Valdovinos; Elizabeth Schieber; Meara McMahon; Lisa Beard; Alyssa Wilkinson; Jaimie Carpenter Journal: J Dev Phys Disabil Date: 2017-11-02
Authors: Rory Sheehan; Laura Horsfall; André Strydom; David Osborn; Kate Walters; Angela Hassiotis Journal: BMJ Open Date: 2017-08-03 Impact factor: 2.692
Authors: E Bruinsma; B J van den Hoofdakker; A P Groenman; P J Hoekstra; G M de Kuijper; M Klaver; A A de Bildt Journal: J Intellect Disabil Res Date: 2020-06-17
Authors: Angela Henderson; Paula Mcskimming; Deborah Kinnear; Colin McCowan; Alasdair McIntosh; Linda Allan; Sally-Ann Cooper Journal: BMJ Open Date: 2020-09-10 Impact factor: 2.692